Sanofi SNY reported third-quarter 2024 adjusted earnings of $1.57 per American depositary share, which beat the Zacks ...

Sanofi’s top-line performance was impressive in the second quarter. Its sales rose 10.2% at CER ... of Dupixent and ...

costly patent expirations of top-selling products as are some rivals. "We've spent five years as a team getting Sanofi to the start line of being a respected R&D machine, and I think the markets ...

and exit the consumer health market as it moves towards a target of generating €10 billion in annual sales from new products by the end of the decade. Sanofi said it expects the deal to close in ...

India’s powerful copycat pharmaceutical industry is set to roll out generic weight loss drugs in the U.K. within weeks ...

Analysts at Zacks Research decreased their Q4 2025 earnings estimates for Sanofi in a research note issued on Tuesday, ...

Recordati said its milestone payment to Sanofi is tied to the achievement of net sales at or above the top end of peak year ... complementary to one of those products, Sylvant.

Sanofi SNY has entered into exclusive negotiations with U.S.-based private equity company Clayton Dubilier & Rice (CD&R) for ...

Birkin bag maker Hermes reported on Thursday a hefty rise in third-quarter sales, continuing to outshine rivals hit hard by a ...

The insulin is facing supply shortages as diabetes patients increasingly turn to GLP-1 weight loss drugs such as Ozempic and ...

Sanofi today announces that the company has entered into negotiations ... Headquartered in France, Opella employs over 11,000 people, operates in 100 countries, and manages 13 best-in-class ...

Sanofi and CD&R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a significant shareholderWith 11,000 talented and passionate people bringing iconic ...